Introduction
In 1997, DRF-2593, later known as balaglitazone, as mall-molecule peroxisome proliferator-activated receptor g (PPARg)a gonist discovered at Dr.R eddy's Laboratories (DRL) in Hyderabad, becamet he first preclinical-stage compound discovered at an Indian pharmaceutical company to be licensed to aW estern company,N ovo Nordisk.
[1] This deal was hailed by many at that time as only the first step on the way to what was expected to become ag rowing flow of successful drugs from India. However,b y2 009, DRL had terminated all its internal discoverya ctivities, without having launched as ingle new drug.
[2] This exit from early in-house pharmaceutical research activities followed the one in 2008 by Ranbaxy Laboratories, and preceded by five years the one of at hird major Indian company, Piramal Enterprises, in 2014. [3, 4] Other Indian companies have abandoned, significantly decreased, or postponed their research efforts in recent years, or are experiencing slow progress, if any,w ith major pipeline products. Proprietary drug discoverya ctivities in India had been initiated since the mid-1990s by companies that had been active in the genericsb usiness, often for several decades. At that time, India was poised to becomet he drug discovery powerhouse of the world, as it had become its generics pharmacy.W ek now today that this grand vision did not materialize. But does this mean the end of the drug discovery industry in India, the "Death of aD ream" as some have claimed? [5] We think this deservesamore thorough analysis. Drug discovery and pharmaceutical R&D in India has been reviewed and analyzed previously,b ut generally from specific points of view,s uch as its historical background, [6] [7] [8] the fate of the big pharma companies, [5, 9] or the impact of process versus product patent output as ac onsequence of the Agreement on Trade-Related Aspects of Intellectual Property Rights( the socalled TRIPS agreement). [10] Other authors have analyzed its socioeconomic impact and public policy implicationsa nd recommendations, [11] [12] [13] [14] [15] drug development in India and in comparison with other emerging countries, [16, 17] drug discovery in private companies and in publiclyf unded institutions, [18, 19] current changes ando pportunities, [20, 21] or out-licensing deals. [22] We recently reviewed contract and collaborative research alliances between Indiana nd globalp harmaceutical companies. [23] Althought hese components represent valuablec ontributions to the understandingo fI ndia's current pharmaceutical industry environment, they lack ac omprehensive analysiso ft he overall scientificp roductivity of proprietaryd rug discoveryi nI ndia, its ongoing achievements in contributing to the globald rug discovery and development pipeline, but also its challenges, the knowledge of which is required if one wants to better understand the country's current situation.
In this review,w ea ttempt to fill this gap by describing and analyzing in ac omprehensive manner the contributions to proprietaryd rug discovery by Indianc ompanies, and by highlighting how the landscape of industrial pharmaceutical research in India, as we know it today,h as evolvedf rom its beginnings over two decades ago, into the current ensembleo f pharmaceutical and biotechnology companies.
Analysis Data and Methods
In our analysis we aim to cover all proprietary research by Indian companies on new chemical entities (NCEs) that have reached preclinical or clinical development stages betweeni ts beginnings in 1994 and mid-2016. We set out by identifying and screening today's top-100I ndian pharmaceutical and biotechnology companies, as assessed from their latest available annualr evenue figures, that is, annualr eports of public companies, and variouss ourcesf or privately held companies (Supporting Information Ta ble 5). [24] [25] [26] [27] We included former top-100 companies with contributions to drug discovery,t hat have been acquired since, that is, three companies. These have been complemented by all early-stage companiesi dentified by an extensive analysiso fI ndian drugd evelopmenta ctivities. We have included severalc ompanies headquartered outsideo f India, butw ith Indian founders, and in general discoverya nd development activities run out of India. Noti ncludedi nt he analysisa re Indian subsidiaries of multinationalc ompanies, althougho ne company is specifically mentioned in the text for its contributions (AstraZenecaI ndia). We have focused our work specifically on small-molecule drug discovery,a nd have excluded biologics, vaccines, botanical drugs, herbale xtracts, This review provides ac omprehensive surveyo fp roprietary drug discovery and development efforts performed by Indian companies between1 994 and mid-2016. It is based on the identification and detailed analysiso fp harmaceutical, biotechnology,a nd contract research companiesa ctive in proprietary new chemicale ntity (NCE) research and development (R&D) in India. Information on preclinical andc linicald evelopment compounds was collected by company,t herapeutic indication, mode of action, target class, and development status.T he analysisf ocuseso nt he overall pipeline and its evolutiono ver two decades, contributionsb yt ype of company,t herapeutic focus, attrition rates, and contributiont oWestern pharmaceutical pipelines through licensing agreements.T his comprehensive analysis is the first of its kind, and, in our view,r epresents as ignificant contribution to the understanding of the current state of the drugd iscoverya nd development industry in India.
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or combination preparationso fe xisting commercial drugs,a nd repositionede xisting products. Prodrugs or polymer-supported forms of marketed drugs, as well as peptides were only included if they were part of broader NCE drug discovery efforts.
Compounds that were in-licensed for clinicaldevelopment purposes from external sources are mentioned in text and tables as integral part of company backgrounds, although they are not included in calculations nor figures. Not included either are drug discoveryp rojectsa tI ndian academic and publicr esearch institutions, unless these wered one in collaboration with pharma companies andl ed to joint patent applications. More comprehensive reports on these have been published elsewhere. [8, 18, 19, [28] [29] [30] [31] For each company, we have analyzed annual reports, as availablef rom company websites or from service providers, [32] company or investor presentations, web pages, press releases, and published patent applications. [33] We have compiled all availablei nformation, including, where available, compound codes, therapeutic areas, modeso fa ction, years in which development phases were initiated, highest stage of development reached,c urrent status of development,a nd eventually status of partnerships or licensing deals with global pharmaceuticalc ompanies. Our analysis reflects the status of the drug discovery pipeline in India by mid-2016.
Severalc larificationsa nd limitations regarding our approach are noteworthy at the outset. First, companies were identified based on their publiclyd isclosed scientific output in terms of development compounds or patent applications. Although we are confident to have included all relevant companies and compounds in our analysis, we cannot exclude minor omissions. Should this be the case, the overall impacto no ur analysis would be small, given the large number of companies and compounds included in this review.
Second,t imelines were assessed based on the years during which the information was disclosed. As this includes annual reports, actual decision dates can be offset by up to af ull year. Further,a st he term "preclinical" can represent stages from early research to preclinical studies enabling Investigational New Drug (IND) applications,w eh ave made efforts to include only compounds beyond the earlyd iscovery stage, that is, our inclusion criteria have been stricter than in an earlierp reliminary short report. [34] Also, as the termination of development is not alwaysp ublicized, we assumedi to ccurred during the year in which the compound disappeared from company reports or presentations.
Finally,a lthough considerable efforts have been made to identify all relevant documents,l imitations in the amounts of publiclya vailable information, andt ime-lags between conducting research and disclosing the results publicly,m eans that some projects might not have been captured correctly in our analysis. Despite these limitations, we strongly believe the data presented provides valuablei nformation, as it gives for the first time ac omprehensive view over two decades of proprietary Indianpharmaceutical R&D.
Drug Discovery in India

Historical background
India'so ldest pharmaceuticalc ompanies were established at the turn of the past century, such as Bengal Chemicals &P harmaceuticals Ltd. (1901), or Alembic Chemical Works (1907) to manufacture quality chemicals, pharmaceuticals and home products. [12] The beginning of drug discovery in the country can be traced back to the second decade of the twentieth century,w ith work on drugs for visceral leishmaniasis, also known as kala-azar,b yU pendranath Brahmachari at the Campbell MedicalC ollege, Calcutta, one of the oldest medical schools to teach European medicine in India, which led to "urea stibamine", introducedi n1 922. [8, 35] The drug was designed to decrease the toxicity of knowni norganic pentavalenta ntimony salts by their incorporation into organometallic aniline derivatives, inspired by Ehrlich's salvarsan, an organoarsenic compound for the treatment of syphilis, that had been introduced in 1910. Urea stibamine waso nly the second successful anti-infective agent to be developed in the world, saved countless patients in the 1920-1930s, and paved the way for the development of more recent antimonials such as sodium stibogluconate, or meglumine antimoniate,b oth on the World Health Organization (WHO) list of essential medicines. [35, 36] Although not ad rug, oral rehydration therapy (ORT), that is, drinking water with controlled amountso fs alt and sugar,c onsidered as "potentially the most important medicala dvance of the [20th] century", [37] was first discoveredb yH .N.C hatterjee, am edical practitioner workingo nc holera patients in Calcutta. Despite being published 1953 in The Lancet, it was unfortunately ignored,only to be rediscovered in 1968 by Western scientists. [38] During the early years after independence, the Government of India, through its Council of Scientific and Industrial Research( CSIR), established the Central Drug Research Institute (CDRI) in Lucknow to lead the country's efforts in drugr esearcha nd development (1951), [8, 39, 40] followed later by other public institutions such as the Regional Research Laboratories in Hyderabad (1956, now Indian Institute of Chemical Te chnology,I ICT), [41] and in Jammu( 1957, now IndianI nstituteo fI nte-grative Medicine, IIIM). [42] CDRI'sm ain focus was to identify lead molecules for tropical diseases and population control measures from medicinalp lants, initially relying on the country's traditional systemso fm edicine such as Ayurveda and Unani, but later expanded to include other plants, andsynthetic smallm olecules. The knowledge of ayurvedic remedies resulted in anumber of drugs or standardized extractswith identified active compounds:" gum guggulu", derived from Commiphora mukul,l ed to the identification of guggulsterones, antagonists of the farnesoid Xr eceptor (FXR) receptorw ith lipidlowering properties, approved 1986 in India as an extract under the name Gugulipid; [40, 43] "brahmi", prepared from Bacopa monnieri,g ave triterpenoid glycoside modulators of the serotonin system as memory enhancers, [44] launched in 1996 as as tandardized extract under the name Memory plus. [40] The search for antimalarials, based on the investigation of Artemisia annua,u sed in traditional Chinese medicine, resulted in arteether,adrug able to cure multidrug-resistant or chloroquine-resistantP lasmodium falciparum, approved in 1998. [40] Further research efforts in India to discover new drugs from plants have been reviewed recently. [45, 46] In the area of small-molecule drug discovery, centchroman (ormeloxifene), as electivee strogen receptor modulator,a nd the world's first nonsteroidal oral contraceptive, introduced in 1990, remains among CDRI'sm ajor achievements. [47] The institute's current challenges such as ad ecrease in the output of new drugs have been discussed recently,a nd potentialo pportunities include the revival of natural products chemistry,r e-emphasizing phenotypica ssays, and strengthening mode of action and target identification capabilities. [19] Notable discoveries made at other public laboratories are enfenamic acid, an anti-inflammatory agent (IICT,1 980), [7] or more recently risorin, ac ombination preparation for tuberculosis (IIIM, 2009) . [48] Al ist of projects toward drug discoveryr esearch at additional CSIR-funded institutionsisa vailable at the Council'sw ebsite. [49] In these early years, the pharmaceutical industry as aw hole, including during the two decades after India's independence, was dominated by multinationalc ompanies, that imported their bulk products,e ven after the setup in 1960 of public sector companies, such as Hindustan Antibiotics Ltd.,a nd Indian Drugs and PharmaceuticalsL td. Notable discoveries made by multinational companies in India were for example reserpine, an indole alkaloid with antipsychotic and antihypertensivep roperties isolated from Rauwolfia serpentina at the Ciba Research Centre in Mumbai (then Bombay,1 952), [50] or forskolin, ad iterpenoid adenylate cyclase activator( 1974), codiscoveredi ndependentlya sc oloneol at CDRI, [45] and flavopiridol, the first cyclin-dependentk inase inhibitor,d erived from the natural product rohitukine (1990s), both at the Hoechst Bombay Research Centre. [51] This changed radically with the Indian Patent Act of 1970, which abolished product patents for pharmaceutical ingredients, recognizing only patents with ad ecreased term( 5-7 years) for process improvements (also called reversee ngineering,a llowing to copy foreign patented drugs), which was much less challengingt han innovative drug discovery. The ensuing rise of local competitors,t he loss of royalties from product patents, and new laws limiting the price of certain drugs, as well as decreasing the ownership of multinationalc ompanies in their Indian enterprises to am aximum of 40 %, led most multinational companies to leave India. [52] This all strengthened the growingl ocal generics industry,w hich became" the world's pharmacy", according to MØdecins Sans Frontires( or Doctors Without Borders) accounting currently for 10 %o ft he globalp harmaceutical production, and 20 %o f global exportsofg enericsinv olume terms. [53] India's "New Economic Policy" of 1991, aimingt ol iberalize the country's economic policies, and its joining the World Trade Organization (WTO)i n1 995, which included the signature of the agreement on TRIPS, with at en year transition periodf rom 1995 to 2005, and the IndianP atents (Amendment)A ct 2005, opened the country again to product patents, and consequently to pharmaceutical innovation. [10] The main industry players recognized the unique opportunitieso ffered by these changes. [20] To reflect the significant changes that the entire industry went througho ver two decades, we have chosen to present our data by companyi nachronologicalo rder,s tartingw ith the large Indian pharma companiest hat were the first to enter the field (Table 1 ). These were followed by contract research organizations( CROs), al imited number of which initiated also proprietaryp rojects, and more recently,b yb iotechnology and startup companiess pecializing in integrated proprietaryd rug discovery.
Initiation of drug discovery at large pharmaceutical companies
Dr.R eddy'sL aboratories (DRL),e stablished in 1984 for the manufacturing of active pharmaceutical ingredients (APIs), and with over 21 000 employees worldwide, had been the first Indian company to launch drug discovery research in 1994. [32, 54] Between 1995 and 2009, DRL reported 27 development compounds,o fw hich 12 reached the clinicald evelopment stage (Supporting Information Ta ble 6a, entries 1-27). It was the first Indianc ompany to out-license, in 1997, am olecule, balaglitazone 1 (DRF-2593), at hiazolidinone (or glitazone)-type PPARg agonistf or the treatment of diabetes, [55, 56] and in 1998 as econd molecule, ragaglitazar 2 (DRF-2725), ad ual PPAR a/g insulin sensitizer for metabolic disorders, [56, 57] to aW estern company,N ovo Nordisk (Figure 1 ). Novo Nordisk eventually abandoned 2 in 2002, when bladder tumors were identified in rats duringt oxicology studies, and returned 1 to DRL in 2004. In 2005 DRL partneredw ith Rheosciences for the furtherd evelopment of 1,w hich in 2007 became the first Indian compound to reach the level of Phase 3s tudies and were completed with DRL'si nternal funds. Although positive clinicald ata were reported in 2010, the compound was abandoned in 2011, after Avandia (rosiglitazone), another compound of the glitazone family developed by GlaxoSmithKline (GSK), had been linked to apparent risks for increased heart attacks, and banned from use in Europe and India in 2010. DRL found additional partners in Novartis (2001) for the development of DRF-4158, ad ual PPARa/g agonist and hydroxymeth- Reviews yl-glutaryl-coenzyme A( HMG-CoA) reductasei nhibitor for the treatment of diabetes (returned to DRL and abandoned in 2003), [58] and in Clintech (2006) for DRF-1042 (3), an orally active camptothecin analogue to treat solid tumors (abandoned in 2007). [59, 60] In 2005, aj oint venturel ed to the creation of Perlecan Pharma, [61] with the aim to develop four DRL compounds:R US-3108, ap erlecan inducer for the treatment of atherosclerosis; [62] DRF-10945, an on-fibrate predominantly PPARa agonistf or the treatment of metabolic disorders; [61] DRL-11605 ap an-PPARa/d/g agonistf or the treatment of obesity and dyslipidemia; [61] and DRL-16536, an AMP-activated protein kinase (AMPK)m odulatorf or metabolic disorders. [63] All four compoundsf ailed in preclinicalo re arly clinical studies and were subsequently abandoned. In 2008, the joint venture was terminated, and DRL had to buy back the shares.T he company entered into ac ollaborationw ith Argenta Discovery to develop novel treatments for chronic obstructive pulmonary disease (COPD), which led in 2007 to ac linical development compound, [64] aP PARg agonist, which was, however,a bandoned the following year.O ther compounds reached the clinical developments tage at DRL, and all failed, including as econd camptothecin derivative,D RF-1644, [65] (abandoned in 2005), and two compounds with an undisclosed mechanism of action for the treatment of dyslipidemia, DRL-21994 and DRL-21995. [54] Fourteen more compounds did not pass the preclinical development stage. [54] After these repeatedf ailures, DRL announced in 2009 the closure of its research activities in Hyderabad, shiftingi ts R&D focus to new drug delivery systems, improved generics and biosimilars. [54] The company continued limited development activities,i ncluding on DRL-17822, an orally activec holesteryl ester transfer protein (CETP)i nhibitor for the treatment of dyslipidemia, [66] which was, however, abandoned 2013 in Phase 2.
Ranbaxy Laboratories,s ince 2015p art of Sun Pharma, was established in 1961, and employed more than 14 000 peoplei n 2014. [32, 67] The decision in the early 1990s to become ar esearch-based company led to the establishment of an ew research center,a nd to the start of drug discoveryp rojects in 1995, which grew to 280 scientists in 2008. [67] The company's first proprietarym olecule RBx-2258 (parvosin) 4, [67, 68] an adrenergic a1r eceptor antagonistf or the treatment of benign prostatic hyperplasia, reached clinical Phase 1s tage in 1999 (Supporting Information Table 6a entries [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] . In 2002, Ranbaxy licensed out 4 to Schwarz Pharma, but the compound was stoppeds hortly after in Phase 2d evelopment due to unconvincing clinicalr esults. In 2003, Ranbaxy partnered with Medicines for Malaria Venture (MMV)f or the developmento fa rterolane or OZ277,s ubsequently called RBx-11160, for the treatment of Plasmodium falciparum malaria,a nd was subsequently grantedaworldwide license (Supporting Information Ta ble 6b, entry 1). [69] [70] [71] The compound reached the Indian market in April 2012a sS ynriam, ac ombinationo fa rterolane maleate and piperaquine phosphate, the first medicine developed (althoughn ot invented) by an Indianc ompany. [72] In 2003, Ranbaxy signed ad eal with GlaxoSmithKline (GSK) for the discovery of treatmentsf or respiratory diseases,w hich led to RBx-10017609, ad ual matrix metalloproteinase-9 and -12 (MMP-9/ MMP-12)i nhibitor, [73] which reached Phase 2c linicals tudies, but has been abandoned since. In 2007, Ranbaxy out-licensed its HMG-CoAr eductase inhibitor RBx-10558 5 to Pharmaceutical Product Development (PPD) for the treatment of hypercholesterolemia. [74] PPD, and subsequently its spin-off Furiex undertook clinical studies, but furtherd evelopment of the compoundw as abandoned in 2011d ue to lack of efficacy in Phase 2s tudies. [75] In 2008, Ranbaxyp artnered with Merck Sharp and Dohme (MSD) for the development of antibacterials and antifungals, but the deal was called off in 2011. Ranbaxy's discoveryg roup produced other proprietary molecules in av ariety of therapeutic areas which reached the stage of clinical development:R Bx-4638 or clafrinast, [76, 77] av ery late antigen-4 (VLA-4) antagonist to treat asthmaa nd COPD;R Bx-7644 (ranbezolid) 6,a no xazolidinone-type protein synthesis inhibitor against bacterial infections; [78] RBx-7796 7,a5-lipoxygenase (5-LO) inhibitor against asthma and allergicr hinitis; [79] and RBx-9841, am uscarinic acetylcholine M 3 receptor inhibitor against urinaryi ncontinence.
[80] Nine additional compoundsw ere stoppeda tt he preclinical development stage. In mid-2008, however,D aiichi-Sankyo acquired am ajority stake in Ranbaxy, which led to the termination of in-house research projects.I n 2015 Daiichi-Sankyo sold the genericsb usiness of Ranbaxyt o Sun Pharma, and in January 2017d ecided to close the remaining R&D site in Gurgaon. [67, 81] Torrent Pharmaceuticals Ltd. was incorporated 1972 with currently over 10 000 employees,a nd focuses on manufacturing and distributing generics, asw ell as on contractm anufacturing,i np articular for the production of insulin for Novo Nordisk. [32, 82] The company inaugurated its To rrent Research Centre (TRC) 1996i nA hmedabad, and launched in-house drug discovery projects the following year,w ith af ocus on metabolic disordersa nd related diseases, including cardiovascular disorders, ischemia, and later COPD. In addition to novel NCE research, To rrent's R&D group focused its efforts on process and formulation development fore xisting APIs, and grew rapidly to around8 00 people, including 130 in discoveryr esearch, with so far three clinicals tage compounds( Supporting Information Ta ble 6a, entries [44] [45] [46] [47] [48] [49] . TRC-4186 8, [16, 83, 84] an advanced glycation end-product (AGE)b reaker compound, to which Novartis took an option in 2002, but returnedt he compound in 2005. To rrentc urrently developst he compound on its own, and completed Phase 2c linical studies in 2015. TRC150094 9, am imetic of diiodothyronine (T2) (T2 mimetic), [16, 85] for the treatment of cardiometabolic risks is currently undergoing Phase 2s tudies. TRC160334 10,ahypoxia-inducible factor (HIF) hydroxylase inhibitor to treat kidney failure and intestinal bowel disease (IBD), is undergoing Phase 1s tudies. [86] Two more compounds failed at the preclinical stage:T RC-282, [87] aN Od onor for cardiovascular disorders, and TRC-8156, [88] ad ipeptidyl peptidase-IV (DPP-IV) inhibitor for the treatment of diabetes. AstraZenecai nitiated in 2005 ac osts haring collaboration with To rrent for the development of drugs againsth ypertension, in which the intellectual property (IP) belonged to To rrent. This led to ap atenta pplication on dual angiotensin II receptor type 1( AT1r eceptor) and endothelin type A( ET A )r eceptor antagonists. [23] Of these one compound, possibly TRC 120038, [89] 11 enteredp reclinical toxicology studies in 2008, althoughnof urtherp rogress has been reported since.
Wockhardt Ltd.,h eadquarteredi nM umbai, was founded in 1967, and manufactures and marketsg enerics and biosimilars with currently about 10 000 employees. [32, 90] The company initiated drug discoveryi n1 997, focusingo nt reatments for bacterial infections, and brought 15 compounds into development, including salts and single enantiomers, of which five progressedi nto the clinic (Supporting Information Ta ble 6a, entries 50-64): WCK-771 or levonadifloxacin 12,s pecifically developed for use in parenteral administration, [91, 92] is the arginine salt of the S enantiomer of the fluoroquinoline class antibiotic nadifloxacin, aD NA gyrase inhibitord eveloped and launched in 1993 by Otsuka for the topicalt reatment of acne. As such, it is not an NCE, but we have included it in the analysis because the compound is an important part of the company's discovery platform, which includes derivatives and prodrugs;W CK-2349 or alalevonadifloxacin 13, [93] an oral amino acid ester prodrug of WCK-771 in Phase 2inIndia;WCK-1152 14, [91] also afluoroquinoline (abandoned);W CK-4873 or nafithromycin, ak etolide-typep rotein synthesis inhibitor completed Phase 1s tudies in 2015 in the US; [90, 94, 95] and WCK-5107 (or zidebactam 15, ad ual penicillin-binding protein 2( PBP2)a nd b-lactamase inhibitor. [96] Five compounds or combination preparations received recently the qualified infectious disease product (QIDP) status, [94] which allows fast-track development and review of the drug application by the US Food and Drug Administration (FDA), and is granted to drugs acting against pathogens which have ah igh degree of unmet needs, such as methicillin-resistant Staphylococcus aureus (MRSA).
Piramal Enterprises Ltd.,a st he company has been known since 2012, was established in 1988 as Nicholas PiramalI ndia Ltd.,a nd enteredd rug discovery research in 1998 with the acquisitiono ft he Hoechst Research Centrei nM umbai. [32, 97] Piramal's R&D activities, focusingononcology,inflammation, metabolic disorders and infections, grew to over 460 scientists in 2012, of which 360 were in NCE discoveryr esearch. The company filed its first patent application in 2002 on inhibitors of cyclin-dependent kinases (CDK) for the treatment of cancer, and in 2005 initiated its first clinicalP hase 1s tudies on P276 (riviciclib) 16, [98] an ovel CDK4 inhibitor,t erminated in 2013 after as etback in Phase 2c linicalt rials (Supporting Information Ta ble 6a, entries 65-80). P1446 or voruciclib 17, [98] as econd CDK4 inhibitor,e nteredc linicald evelopmenti n2 008. In January 2007P iramal announced ac ollaboration with Eli Lilly &C o. on the preclinical and clinicald evelopment of two in-licensed Lilly development candidates for the treatment of metabolic disorders:P 1201 (mode of action not disclosed) entered Phase 1i nE urope, was stopped in 2013, [97] and P2202, a1 1 bhydroxysteroid dehydrogenase type1(bHSD1) inhibitor,w hich enteredP hase 1i nE urope in 2009, reached Phase 2i nI ndia and Canada, but has been abandoned since (Supporting Information Table 6b entries 2-3). [97] In 2007, Piramal engagedi na n integrated oncology drug discovery collaboration with MSD to discovera nd develop novel treatments for cancer up to clinical proof-of-concept studies, which led to PL225B, [99] [100] [101] an oral insulin-likeg rowth factor 1r eceptor (IGF1R)i nhibitor,s tructurally possibly related to sulfonyl-indole derivativesw hich reached Phase 1, [102] but which has probablyb een abandoned in 2014. As econd IGF1R project ("Target Y") did not pass the candidate selection stage. Piramal's naturalp roducts collection, with more than 53 000 microbial strains and 7300 plants and extracts (2011f igures) from diverseh abitats, [97] has been made availablef or screening to externalp artners, of which two, Pierre Fabre and Oncotest, have been disclosed publicly. [103, 104] In addition to five compoundsw hich were abandonedi np reclinical studies, several other Piramal compounds entered clinical trials:P 1736 18,anon-thiazolidinedionei nsulin sensitizer for the treatment of diabetes, discoveredu sing phenotypic screening; [105] P1961A, ad ualC DK4/HIF1a inhibitor for the treatment of cancer; [97] P2745, ap otent inhibitor of the transforming growth factor b (TGF-b)p athway for the treatment of hematological malignancies (abandoned in Phase 1i n 2013); [106] P3914, ad ual-action naproxen-based cyclooxygenase inhibitor linked to an NO donor for the treatment of pain; [107, 108] P7170, or panulisib 19, [109, 110] ap hosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) and Alk-1 inhibitor for the treatment of cancera nd inflammation, partnered with MSD;P 7435, [97] ap otent and highly selective, oral diacylglycerol O-acyltransferase 1( DGAT1) inhibitor for the treatment of diabetes; and P11187, [97] aG -protein-coupledr eceptor 40 (GPR40)a gonist against metabolic disorders. After an ame change to Piramal Healthcare Ltd. in 2007, the company evolved rapidly over the following years, by selling in 2010 its generics business to Abbott, by acquiring in 2011O xygen Healthcare for drug discovery services,r ebranded as Piramal Discovery Solutions, andi n2 012 Bayer's molecular imaging development portfolio which becameP iramal Imaging. [97] In August2 014, Piramal announced the closure of its drug discovery activities in Mumbai, essentially terminating all earlystage R&D activities,a ffecting close to 200 scientists. [111] An attempt was made to out-license the five at that time remaining Phase 1c ompounds, but most were later abandoned, and only the DGAT1 inhibitor and the GPR40 agonist completed Phase 1 studies in 2014, although no further information has been published. [97] Twoe arly candidate compounds were licensed to Krish Biotech in 2015 (see below).
Dabur Research Foundation (DRF) was incorporatedi n 1979 as the healthcare R&D branch of Dabur,acompany active in ayurvedic medicines and consumerg oods in India since 1886. DRF established preclinical labs in 1994, and initiated drug discovery research in 1998. [32, 112] The company filed as eries of patent applications in 2000o nt he use of neuropeptide analogues for the treatmento fc ancer,b ut did never developed ap roprietary NCE, as DRF-7295, [113] Dabur's first socalled NCE, was actually am ixture of peptides derived from vasoactive intestinal peptide( VIP), bombesin, substance P and somatostatin, known to be overexpressed in variousc ancers, which entered Phase 1c linical trials as ap otentiala nticancer vaccine in India in 2002, followed by reportedlys uccessfulP hase 2t rials initiated in 2004. However,n op rogress has been reported since 2008, and it has most likely been abandoned. When in 2008F resenius Kabi acquired Dabur Pharma, the Dabur ResearchF oundation was spun out and becamea ni ndependent drug discoverys ervicesc ompanyi n 2010.
Sun Pharma was founded in 1983 in Vapi, and established its first research centeri n1 993. With the recent acquisition of Ranbaxyf rom Daiichi-Sankyo, and more than 30 000 employees in 2016, Sun has become India's number one pharmaceutical company,a nd the world's fifth largest global specialty generics company. [114] Sun enteredd rug discovery in 1999, working on NCEs and new drug delivery systems (NDDS). The research department, by then 80 scientists, movedi nto an ew R&D center in 2004. In 2007, the research department was establisheda sa ni ndependent company,S un Pharma Advanced Research Company (SPARC) with more than 120 scientists, and has grown since to 275 scientists. [115] Sun's research has produced so far eight developmentc ompounds, of which three reachedthe clinical stage (Supporting Information Ta ble 6a, entries 81-88). SUN-1334H 20, [116, 117] ap otent antihistamine, reachedP hase 2c linicalt rials in the US, but has been abandoned in 2013. Prodrugs with undisclosed structures of baclofen (SUN-09,r eached Phase 1i nI ndia) and gabapentin (SUN-44, preclinical stage),b ut have not been progressed further. [118] Sun has been workingo ns o-called "soft" corticosteroids, [119] with hydrolyticallyand metabolically labile substituents, including SUN-461, abandoned in Phase 1, [114] and SUN-597 21, [120] [121] [122] which is undergoing Phase 1s tudies for dermatology,b ut has been abandoned for nasal and inhalation indications. SUN-L731, an oral leukotriene D4 (LTD4) antagonist, [123] entered preclinicald evelopment, but has been abandonedi n2 016. The company hasa lso been developingp reclinical stage mutantselectiveB cr-Abl tyrosine kinase inhibitors, [124, 125] such as SUN-K706, devoid of vascular endothelial growth factor receptor 2 (VEGFR-2) inhibition and presumably less likely to lead to side effects observed with other compounds of the family,i np articular arterial thrombosis, [115] and, more recently SUN-K954, af ollow-on compound with ah igher selectivity toward the T351M mutant. [126] Sun Pharma filed patent applicationsw ith Bioprojet (France) on S1P1 receptor agonists to treat transplant rejection, autoimmune disorders, and inflammation, [127] [128] [129] althoughn od evelopment activity on these compounds has been identified.
Alembic Ltd. is one of the oldest pharmaceutical and chemical companies in India, with its foundation in 1907 to manufacture tinctures and alcohol. [32, 130] The company grew since the 1960s with the manufacturing and commercialization of antibiotics, including penicillins, cephalosporins andm acrolides. Alembic entered proprietaryd rug discovery in 1999t hrough ac ollaborationw ith the National Chemical Laboratory( NCL) in Pune on antimicrobialm acrolides, ap roject which has likely been abandoned around 2003, after as trategic switch of the company to contract research under the name of BioArc Research Solutions. In 2008 Alembic invested in two drug discovery companies, Incozen Therapeutics in Hyderabad, and Rhizen Pharmaceuticalsi nS witzerland( see below). Twoy ears later,i t split off itsp harma business under the name of Alembic Pharmaceuticals Ltd.,k eeping bulk drug manufacturing and real estate activities under Alembic Ltd.
ZydusC adila Healthcare (or Cadila Healthcare), the pharmaceuticala rm of what became knowna st he Zydus Cadila group, headquartered in Ahmedabad, was initially founded as Cadila Laboratories in 1952, and was incorporated in 1995 after separating from Cadila Pharmaceuticals (see below). The company had over 15 000 employees worldwide in 2016, with operations in generics, active pharmaceutical ingredients, animal healthcare products,a sw ell R&D in the areas of NCEs, formulation, biosimilars and vaccines. [32, 131] The Zydus Research Centre, established in 2000 in Ahmedabad, houses around 400 scientists, out of whicha bout 250 dedicated to NCE research. Zydus Cadila initiated its NCE discovery programs in 2000 with as trong focus on metabolic disorders and, to al esser extent, inflammatory diseases, and disclosedatotal of 15 drug candidates,o fw hich 13 movedi nto clinical development stages (Supporting Information Ta ble 6a, entries 89-103). ZYH1 (INN saroglitazar,t rademark Lipaglyn) 22, [132] aP PARa/g agonist, was approved for the treatment of diabetic dyslipidemia in 2013 in India as the first NCE discovered and developed by an Indian company.I ti sc urrently under development for otheri ndications, including nonalcoholic steatohepatitis (NASH). Zydus Cadila currently haso ne compound in Phase 2s tudies in India (ZYH7, aP PARa agonist), [131] and two at Phase 1l evel: ZYDPLA1, ao nce-a-week DPP-IV inhibitor for diabetes, [133] in the US, and ZYAN1, ah ypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor for the treatment of anemia, [134] commonly observed in chronic kidney disorder.I na ddition, ZYTP1, ap oly(ADP-ribose) polymerase (PARP) inhibitor has recently been approved for the initiation of Phase 1t rials in India. [135] Nine additional compounds progressed into clinical studies, but most were abandoned during Phase 1s tudies. The majority focused on treating diabetes via different modes of action: ZYH2,adual PPARa/g agonist; [131] ZYO1, ac annabinoid receptor type 1(CB 1 )antagonist, [136] stopped in Phase 2; ZYD1, apeptidic GLP-1 agonist; [137] ZYOG1, an oral peptidomimetic GLP1a gonist; [138] ZYGK1, ag lucokinase activator; [139] and ZYG19, aG -protein-coupled receptor 119( GPR119) agonist. [140] Others targeted dyslipidemia (ZYT1, at hyroidh ormone receptor b (TR-b)a gonist), [141] inflammation and pain( ZYI1,m ode of action not disclosed,a bandoned in Phase 2), [142] or osteoporosis (ZYPH0907, an oral parathyroid hormone( PTH) receptor agonist). [143] The company also entereds everal collaborative drug discoverya lliances, [23] including with Karo Bio on inflammatory disorders (2008) whichl ed to ap atent application, [144] and Lilly on cardiovascular disorders (2009), [145] although both collaborations have been terminateds ince.
Cadila Pharmaceuticals,the privately owned sister company after the parent company's split-up into two separate entities in 1995, has been considerably less involved in NCE research. [146, 147] It developed for example, Polycap, af ixed-dose combination treatment based on existing drugs to treat heart attacks, Mycidac-C, al ung cancer vaccine, or Risorin to treat tuberculosis with acombination of rifampicin and piperine, an alkaloid extracted from pepper whose bioavailability enhancing properties had been discoveredatthe Regional Research Laboratory,n ow Indian Institute of Integrative Medicine (IIIM), Jammu. [18] The company also engaged in preclinical and clini-cal development projects with Western biotechnology companies. [148] FDC Ltd. manufactures and sells APIs and formulations, and initiated efforts in R&D around2000, focusing on academic collaborations, in particularwith the National Chemical Laboratory (NCL) in Pune, on antifungals, which has led to as eries of joint patent applications,i ncluding on Fluconazole analogues. [32, [149] [150] [151] [152] No progress, however,h as been reported on NCL-FDC-101, an early-stage compound disclosed in 2006, which is likely to have been abandoned, asn or eference has been made to drug discovery in annualr eports since 2013 (Supporting Information Ta ble 6a, entry 104). [149] JB Chemicals &P harmaceuticals Ltd. (JBCPL),ap roducer of generics and bulk drugs established in 1976, initiated NCE research around the year 2000, working on NSAIDS including cyclooxygenase-2 (COX-2) inhibitors for the treatment of inflammation; [32, [153] [154] [155] In 2004 the company reportedt hree compounds in preclinical development, including JB-7/G (Supporting Information Ta ble 6a, entry 105). [156] In the same year,h owever,w ork on COX-2 inhibitors was badly affected worldwide by the withdrawal by MSD of rofecoxib (trademarkV ioxx) due to the increased risk of cardiovascular side effects, and development of JB-7/G was discontinued. JBCPL abandoned NCE drug discoverys ubsequently,a sn of urtherr esearch projects have been mentioned in annual reports,a nd no furtherN CE patentshave been filed since 2006.
Cipla Ltd.,f ounded in 1935, is the world's largest manufacturer in terms of volumeo fa ntiretroviral drugs to fight HIV. [157] The company did not invest in internal NCE research, but licensed two compounds for commercialization from Central Drug Research Institute (CDRI), that is, gugulipid to treat hyperlipidemia( 1987), [39] and chandonium iodide, an euromuscular blockinga gent (1994). [8] Ac ollaboration aroundt he year 2000 with Universityo fM umbail ed to patentso na ntihistamines, [158] and antibacterials, [159] but these compoundsw ere abandoned later,w ithouta ny information being disclosed on their development status. Cipla invested in stem cell research in 2010 through as trategic alliancew ith Stempeutics Research, and in 2014 launched its business-incubating unit, Cipla New Ventures, through which it invested in Chase Pharmaceuticals Corporation, ane arly-stage US-based development company, to finance Phase 2s tudies of the company's lead Alzheimer's disease (AD) treatment drug CPC-201. [160] Glenmark Pharmaceuticals,w as founded in 1977 for the manufacturing of APIs and generics, and employs over 12 000 people. [32, 161] In 2001, the company initiated small-molecule drug discovery in the in newly established R&D center in Navi Mumbai, focusingw ithc urrently around 300 scientists on metabolic disorders and airway diseases, and in 2004 inaugurated its biologicsr esearch centeri nS witzerland, [32, 161] with currently 50 researchers. Glenmark'ss mall-molecule research has delivered so far 19 developmentc ompounds,o fw hich eight moved into clinicalt rials, including severalp hosphodiesterase type 4( PDE4) inhibitors for airway diseases( Supporting Information Table 6a , entries [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] . [162] One of these, oglemilast (GRC-3886) [163, 164] 23 was Glenmark's first compound to be outlicensed, to Forest Laboratories in 2004 for the North American market, followed in 2005 with Teijin for Japan. In 2009 the compound was abandoned in Phase 2. Glenmark has been successfuli no ut-licensing the rights to further compounds:t o Merck KGaA in 2006 for melogliptin (GRC-8200) 24, [165, 166] aD PP-IV inhibitor for type 2d iabetes, which was abandoned after Phase 2s tudies in 2011; to Lilly in 2007 for GRC-6211 25, [167, 168] at ransient receptor potentialc ation channel type V1 (TRPV1) antagonist for various diseases, stopped in Phase 2 studies the followingy ear;m ore recently,t oS anofii n2 010 for GRC-15300 (or SAR292833), globally the first transient receptor potentialc ation channel type V3 (TRPV3) antagonist to enter clinical trials, for osteoarthriticp ain. [169, 170] In 2012G lenmark signed an option agreement with Forest Laboratories for the discoverya nd developmento fn ovel microsomal prostaglandin Es ynthase-1 (mPGES1) inhibitors for the treatmento f chronic inflammatory conditions, with GRC-27864 currently in Phase 1. [171] [172] [173] [174] Additional compounds which reached the clinical stage are revamilast (GRC-4039) 26, [175, 176] also aP DE4 inhibitor,s topped in 2012 at the Phase 2s tage;t edalinab (GRC-10693) 27, [177, 178] ac annabinoid CB 2 receptor agonist for the treatment of inflammatorya nd neuropathic pain (abandoned in Phase 1in2 011);and GRC-17536, [179] atransientreceptor potentialc ation channel, subfamily A, member 1( TRPA1)i nhibitor for respiratory disorders, that reached Phase 2s tudies, [180] exploring ap otassium salt and prodrugs. Glenmark also actively in-licensed development compounds for the markets in India and other emerging countries. This includes, in 2005 Napo Pharmaceutical's antidiarrheal product crofelemer,apurified oligomeric proanthocyanidin( M r up to 9kDa) which blocks two unrelatedc hloride channelsi nt he gut, approved in 2012, [23] or monoclonal antibodies to build up ab iologics pipeline (Supporting Information Ta ble 6b entry 4). [161] Lupin Ltd.,f ounded in 1968, is one of the world's largest producerso fg eneric antituberculosis drugs with more than 16 000 employees worldwide. [32, 181] Lupin opened its R&D center in 2001 in Pune, with af ocus on NCE drug discovery, process chemistry for generics, research in dosagef orms, and advanced drug delivery systems. Lupin's first therapeutic focus was broad and included cardiovascular (antimigraine), anti-infectives (antituberculosis, bacterial resistance), respiratory (antiasthma) and dermatological (psoriasis) diseases.T he company invested significantly into the development of herbal drugs, and claims to have identified the active constituent of Desoris, ap urified arabinoglycan-protein molecule code-named LL-4218 (desoside-P) [182] which was broughti ntoP hase 2( Supporting Information Ta ble 6a, entries [125] [126] [127] [128] [129] [130] [131] . Twof urther molecules were abandoned:s udoterb (LL-3858) 28, [183, 184] an ovel small-molecule antibacterial agent that completed Phase 2s tudies in India in late 2013, and LL-6531, ap reclinical stage PPAR modulator. [181] Lupin's R&D was entirely restructured in 2010, with the launch of new projects in the therapeutic areas of metabolic and endocrined isorders, pain and inflammation, autoimmune diseases,c entral nervous system (CNS) including cognition deficits, oncologya nd antivirals.I n 2015 the company's R&D department counted over 300 scientists, of which an estimated 130 in NCE drug discovery.A mong the new projects, four are undergoing clinical development in European countries, [181] and are availablef or out-licensing: LND101001, aP hase 2 a7n AChR modulator for cognitive deficits such as in AD, [185, 186] LNP1892, aP hase 1c alcium-sensing receptor (CaSR) modulator for the treatment of primary hyperparathyroidism, [187] LNP3794, am itogen-activated protein kinase kinase (MEK) inhibitor,w hich completed aP hase 1s tudy in terminally ill patients in the UK, [188] andL NP1955, ac alcium release-activated channel (CRAC) modulator for the treatment of autoimmuned iseases such as rheumatoid arthritis and psoriasis, which has successfully completed Phase 1s tudies, and is enteringP hase 2p roof-of-concept studies. [189] RelianceL ife Sciences was established in 2001 as the biopharmaceutical arm of Reliance Industries, one of India's largest industrial conglomerates. [190] In addition to working on stem cell technologies, since 2002, the company filed patent applicationsf rom 2005 to 2007 on small-molecule compounds to treat lipase-mediated diseases, inflammation and cancer. [191] [192] [193] These included early-stage compounds such as RSCL-0409, ag lucodisaccharide, [194] or RSCL-0520, ap henanthrene derived from Eulophia ochratea, [195] both inhibiting TollLike receptor (TLR) signaling pathways (Supporting Information Ta ble 6a, entries [132] [133] . The compounds are likely to have been abandoned around 2010 when the company's research focus shifted to siRNA-mediated approaches to treat cancer. [196] Orchid Chemicals &P harmaceuticals,o rO rchid Pharma since its recent name change in 2015, was established in 1992 in Chennai to manufacture antibiotics, and enteredd rug discovery in 2001 with projects in the areas of anti-infectives and treatments for pain. [32, 197] In 2002, the company engaged in aj oint venturet od evelop US-based firm Bexel Biotechnology's BLX-1002,a no ral, non-PPAR AMPK activator for the treatment of diabetes, [198] later repositioned for NASH (2012), but no further progress hasbeen reported recently. [197] In 2008, Orchid invested in DiakronP harmaceuticals, aU S-based company that had an exclusive license to MSD'si nvestigational oral anticoagulant drug, ad irect thrombini nhibitor later known as DPOC-4088 (or DP-4088), [199] which reached Phase 1c linical studies in Europei n2 012 (Supporting Information Ta ble 6b, entries [5] [6] . [200] The company's own internal discovery efforts had ab road therapeuticf ocus, covering infectious diseases, inflammation, pain, oncology,m etabolic disorders, and CNS diseases. OCID-2987, [197, 201] aP DE4i nhibitor for the treatment of inflammatoryd isorders such as COPD, completed successfully Phase 1s tudies in Europei n2 012, and OCID-4681 29, [202, 203] ah istoned eacetylase( HDAC) inhibitor for cancerh ad received approvali n2 011f or Phase 1s tudies for solid tumors in India, but we assume both have been abandoned, as cancer and inflammation are not mentioned in the company's latest annual reports. [197] Twoa dditional compounds were abandoned at the preclinical stage:O CID-5005,aSTAT-3/IL-6 inhibitor foro ncology,a nd au nnamed Th1/Th2 cytokines ynthesis inhibitor for inflammation (Supporting Information Ta ble 2a, entries [134] [135] [136] [137] [138] . [197] Financiali ssues led Orchid,a so f2 009, to sell parts of its business to Hospira (now part of Pfizer). As ac onsequence, no progress has been reported on its discoveryp rograms since 2010, and no furtherN CE patent applicationh as been published since 2012. However,i n2 013 Orchid licensed its broadspectrum b-lactamase inhibitor OCID-5090, az witterionic Nmethylated tazobactam derivative, to the German Allecra Therapeuticsf or a2 0% stake in the company,f or use in combination with antibiotics to treat multidrug-resistantg ram negative bacteria. [204] [205] [206] [207] Allecra's lead compound AAI202, ac ombination of cefepime and AAI101/OCID-5090 30,i sc urrently in Phase 1 studies in France. [208, 209] Suven Life Sciences Ltd.,i ncorporatedi n1 989 as Suven Pharma, with the goal to offer contract research and manufacturing services,c hanged its name in 2003, the year it initiated internal drug discovery efforts, focusinge xclusively on the central nervous sytem (CNS). [32, 210] Thec ompany enteredi nto ag lobalc ollaborative research partnership in 2006 with Eli Lilly,f ollowed by as econd deal in 2008, although nothingh as been disclosed on the outcome of this collaboration. [211] Suven filed its first IND application in 2007 for lead compound SUVN-502, as erotonin 5-HT 6 receptor antagonist for the treatment of mild cognitive impairmenta ssociated with CNS diseases such as AD, Parkinson'sd isease (PD) or schizophrenia. Phase 1s tudies were completed in 2009, and after unsuccessful attempts to out-license the compound, Suven initiated Phase 2a trials on its own in 2015 (Supporting Information Ta ble 6a, entries 139-153). [212] [213] [214] SUVN-G3031, ah istamine H 3 receptor antagonist for cognitive impairment completed Phase 1s tudies in 2015 in the US. [212, 215] SUVN-D4010, ap artial 5HT 4 agonist for the same indication entered Phase 1t rials in the US in in 2015. [212, 216] Preclinical stage compounds include a4 b2n AChR antagonists such as SUVN-911, or cannabinoid CB 2 receptor agonists. [212, 217] Natco Pharma was incorporated in 1981 with the objective to manufacture conventionala nd controlled releaseg enerics, and inaugurated in 1997 the Natco Research Centre( NRC) in Hyderabad. [218] In 2003N atco launched its oncology division with generic imatinib (Gleevec), and initiatedi n-house discovery research, withafirst patent filing in 2004 on Bcr-Ablk inase inhibitors. In 2012 Natco was awarded the first Indian compulsory licensef or Bayer's and Onyx Pharmaceuticals' sorafenib. The company has currently two compounds in clinical development:NRC-AN-019 31, [219] an analogue of imatinib, which received orphan drug status for chronic myelogenous leukemia (CML), glioma and pancreatic canceri n2 011b yt he FDA (undergoing Phase 2t rials in India), and NRC 2694 32, [220] an erlotinib (Tarceva) analogueE GFR kinase inhibitor in Phase 1t rials in India for late-stage solid tumors (Supporting Information Ta ble 6a, entries154-155). NRC-AN-015, an earlier Bcr-Ablt yrosine kinase inhibitor,h as been abandoned at the preclinical stage. [218] Panacea Biotec,f ounded 1984, has become one of the top-10 vaccinep roducersi nI ndia, in addition to manufacturing APIs, and the marketing of generics. [221] The company has notably played ak ey role worldwide in polio eradication campaigns. It currently counts around2 500 employees, down from 3300 in 2014, of which 230 were in R&D.I th as four R&D centers, including the LAKSH Drug Discovery R&D Centre in Mohali,P unjab, established in 2005 focusing on metabolic disorders, diabetes and infectious diseases.I n2 007 CNS diseases were added as an indicationt hrough ac ollaboration with Punjab University,a nd the NCE discovery group grew to over 100 peoplei n2 011. The company started filing NCE patents as of 2008, in particularo ni nhibitorso fD PP-IV ando fs odiumglucosec o-transporter-2 (SGLT2) for the treatment of diabetes, and on novel oxazolidinone antibacterial agents to treat infectious diseases. Its research efforts have led to four development compounds, of which PBL-1427, aD PP-IV inhibitor reachedP hase 1c linicalt rialsi nI ndia in 2012 (Supporting InformationT able 6a, entries [157] [158] [159] [160] . [222, 223] Panacea's turnover in fiscal year 2014-2015 decreased to less than half of what is was in 2010-2011, after the company was hit by quality management issues with its vaccine manufacturing. As ac onsequenceo ft he severe drop in income, internal R&D wasd ecreased, in-house drug discoveryw as halted, and attempts were made to out-license or partner existing internal projects. In 2014 the company adopted an ew,i ntegrated contract research service model under the brand name of Panacea Life Sciences. Panacea's current pipeline includes, in addition to PBL-1427, one additional unnamed compound at the preclinical stage. [221] Matrix Laboratories was set up in 2000 to manufacture generic APIs, and grew by domestic and international acquisitions to become in 2006 ranked 10 of Indian pharmaceutical companies in terms of market capitalization. [32, 224] At the end of 2004, Matrix signed ac ollaboration agreement with aRigen, aJ apanese biotech company focusing on anti-infectives research, to supply compounds for screening.D uring the following year,t he company initiated internal drug discoveryp rograms targeting asthma and metabolic disorders, later expanding into treatments of pain. Matrix'sf irst patenta pplications were filed in 2006 on DPP-IVi nhibitors, with the lead compound MX-6001, and phosphodiesterase( PDE) inhibitors, including PDE4 inhibitor MX-4007, followed in 2008 on vanilloid receptor modulators (SupportingI nformationT able 6a, entries [161] [162] . [225] [226] [227] [228] In 2006, Matrix, at that time with 2000 employees,o fw hich 200 scientists in R&D, was acquired by Mylan. Drug discovery and development was subsequently abandoned, and did not appear in later annual reportso ft he company.
Hetero Drugs is one of the top-10 pharmaceutical companies, and the largestp rivatelyh eld Indianp harmaceutical company. [229] Founded in 1993, with currentlyo ver 15 000 employees, it is the world's largest manufacturer of antiretroviral drugs, accounting for a2 5% share of the global antiretroviral production.H etero ResearchF oundation (HRF), the R&D arm of the Hetero Group companies, employs 400 scientists focusing on process and analytical R&D, and more recently on discovery research. The company's main areas of discovery, initiated around 2006 include treatments against human immunodeficiency virus (HIV), hepatitis Cvirus (HCV),cancerand diabetes. HRF has been particularly activei na nti-HIV drug discovery, where it started filing patentsi n2 008 on compounds with different mechanisms of action, including nucleosides, [230] peptidomimetic protease inhibitors, [231] and more recently on triterpene maturation inhibitors. [232] In 2012 HRF claimed to have two novel compounds ready to enter Phase 1c linical studies (Supporting Information Table 6a , entries [163] [164] . [233] However,n oi nformation has been publiclyd isclosedo nt he progress of these compounds. Jubilant Life Sciences is the pharmaceuticals and life sciences arm of the vast Jubilant Bhartia Group,aconglomerate with over 36 000 employees encompassing diverse sectors such as oil, gas, automobiles, aerospace, food, agrochemicals, and polymers. Jubilant entered the drug discovery services businessi n2 003. [234] With 6100 employees worldwide, of which around 700 in discoverys ervices,t he company has developedf rom am anufacturer of bulk chemicals, incorporated in 1978, into one of the main research and development service providers in India. The company has been engaged in multiple drug discoveryc ollaborations, includingL illy,A mgen, Forest, Orion, Endo, or Johnson &J ohnson (J&J), and in 2016, initiated as trategic alliancew ith Sanofi to discover drugs for metabolic disorders. [23, 235] More recently Jubilant started transforming itself into ad ual-business model company,w ith the creationi n2 007 of JubilantI nnovation, the company's branch for the discoverya nd development of proprietaryo rc o-owned molecules. The first effort to enter drug development, was by partnering with CGI Pharmaceuticals in 2008 for the development of CGI-1842 (subsequently knowna sJ I-101), at yrosine kinase inhibitor targetings electively vascular endothelial growth factor receptort ype 2( VEGFR2), ephrin type-B receptor 4( EphB4) and platelet-derived growth factor receptor b (PDGFRb), which reached aP hase 1/Phase 2s tage trial in solid tumors in the US in 2012, but has been abandoned since for lack of efficacy (Supporting Information Ta ble 6b, entry 7). [236] Since 2014, the company has been disclosing its proprietary oncology-focused drug discovery projects, on EGFR kinase inhibitors (JIEM-0186), [237] dual lysine-specific histoned emethylase (LSD1)-histone deacetylase inhibitors (JBI-097), [238, 239] and bromodomain and extra-terminal motif (BET) inhibitors (JBET-050). [240] Jubilant's BETB RD4 inhibitor program,i ncluding lead compound CK-103, has recently been licensed to Checkpoint Therapeutics (2015) (SupportingI nformation Ta ble 6a, entries 165-167). [241] Elder Pharmaceuticals,f ounded 1989, and active in the manufacturing of APIs and the distribution of products for women's healthcare, woundc are and nutraceuticals, filed two patentsi n2 008 with Poona College of Pharmacy on anti-inflammatory agents, [242] and on thiazolidinonec ompounds for the treatment of diabetes. [243] The company has had serious financiali ssues, and is currently facing bankruptcy. [244] No information is availablei na nnualr eports on any internal drug discovery or development activities. [32, 245] IPCA Laboratories,amanufacturer of APIs andg eneric formulations, and market leader in India for antimalarials, entered Information Table 6b , entries 8-9). [246] The company initiated inhouse drug discovery projects in 2009 to developt reatments for pain, ulcers, and malaria and thrombosis,a nd claimed to have two compounds in their pipeline fort hrombosis and ma- Reviews laria in 2012, butn oi nternal compound appearst oh ave passed the research stage so far. [247, 248] MankindP harma,f ounded in 1995, has become one of the top-five privately held Indian pharma companies. It currently counts more than 11 000 employees, of which 200 in its R&D Centre in Manesar,e stablished in 2011, focusingo np harmaceuticald evelopmenta nd new drug discovery research. [249] The company claims to be active in five new drug discoveryp rojects in the areas of diabetes, arthritis anda ngina,b ut no information on the research programsh as been disclosed, nor has there been any publishedNCE patent application.
Alkem Laboratories was founded in 1973, and until recently ap rivately held pharmaceutical company.
[250] Alkem initiated drug discovery efforts in 2012 in the area of infectious diseases. [251] Am ore recent focus has been on the development of cathepsin Ki nhibitors for the treatment of osteoporosis, with Alkem-43 as ap otentialc andidate compound (Supporting InformationT able 6a, entry 168). [252] [253] [254] Alkemc losed its drug discovery efforts in preparation of its successful initial public offering in 2015, and has attempted to license the project.
EmcureP harmaceuticals was incorporated in 1981, and counts among the top-30 Indian pharmaceutical companies with over 9000 employees. [255] The R&D team counts4 00 scientists, focusing on API development and formulations research. Around 2014, the company started a" New Drug Discovery Research" group, withs of ar as inglep ublished patent application on acid secretion inhibitors. [256] No further information is currently available on Emcure'sd rug discovery efforts.
Finally,a nd although not included in our analysis as the Indian subsidiary of am ultinationalc ompany,i ti sw orth mentioning the contributions, primarily driven by Indian scientists, of what has been considered by some in the country as an "iconic lab", AstraZeneca India. [257] At at ime when the R&D centers of other Westernc ompanies had left the country,A straZeneca, formed by the mergero fA stra and Zenecai n1 999, chose to build on the existing Astra ResearchC entre India (ARCI) in Bangalore. [258] Established in 1987 as an onprofit organization to address the problem of infectious diseases in developingc ountries, the company initially developed diagnostic tools to identify parasitic diseases, soon followed by drug discovery projects in collaboration with Astra Swedeni nt he field of antimalarial and antimycobacteriala gents. [259] The merger resulted, in addition to ac hange in name to AstraZenecaI ndia Pvt. Ltd.,i namodified remit with af ocuso na ntituberculosis drug discovery.T he Bangalore group successfully delivered its first development compound, AZD5847, an ovel oxazolidinone antibiotic,t hat enteredP hase 1s tudiesi n2009. [258, 260, 261] This was followed in October 2014, through ac ollaborationw ith MMV initiated in 2010, by MMV253 (or AZ13721412), at riaminopyrimidine V-type H + -ATPase inhibitor,anovel class of fastkilling and long-acting antimalarials, as preclinical development compound in 2014. [262, 263] The collaborationw ith TB Alliance, also initiated in 2010, yielded at hird development candidate, TBA-7371, ap otent inhibitor of DprE1, currently undergoing preclinical development. [264, 265] By January 2014 however,A straZenecah ad announced the closure of its Bangalore R&D center,i mpacting 168 employees in drug discoverya nd process R&D. [257] The company continued the clinicald evelopment of AZD5847, which entered Phase 2s tudies in 2012, but was abandoned in 2015. [258] TB Alliance found ap artner in Lilly for the further preclinical development of TBA-7371, and MMV recovered the rights to MMV253, which was partnered with another Indian company,Zydus Cadila. [266] 3.3. From contract research to proprietary discovery projects India becameah ub for drugd iscoveryc ollaborations in the late-1990s when global pharmaceutical and biotechnology companies started outsourcing non-IP-sensitive chemistry such as chemical libraries, intermediates and reference compounds. Cost arbitrage, togetherw itht he availability of synthetic chemistry expertise, and existing knowhow from the generics development and manufacturing business, hadl argely been the drivers initially,a nd still are, to al arge extent, even though Western companies are looking increasingly for added value beyondc heap labor.T he service offerings expanded beyond chemistry into biology and pharmacology,a nd an umber of deals gradually evolved into IP-generatingc ollaborations with Indian inventors, and often into collaborative, integrated drug discoverya lliances, with, in selected cases,t he elements of risk and rewards haring.
In addition to ag rowingn etwork of smaller companies,t his led to the rise of several large contract research companies. Those that did not initiate proprietary in-house projects are not included in our analysis, although some of the largest deserve being mentioned for their contributions in support of globald rug discoveryp rojects. [23] Syngene International Ltd., founded in 1994, is the contract research subsidiary of Biocon, and has engaged in collaborations with an umber of pharmaceuticala nd biotechnology companies, of which by far the largest, witho ver 550 scientists, has been signedi n2 007 with Bristol-Myers Squibb (BMS), covering abroad range of integrated drug discoveryand development services. [23, 267] This was followed by Abbott Nutrition (2010), Baxter (2014), and recently by Amgen (2016), all with dedicated centers. [268] TCG Lifesciences (TCGLS) was established as Chembiotek Research in 1998 and started offering chemistry services from its facilities in Kolkata in 2001, then expanded into multiple service areas, including biology,p harmacology,D MPK, clinical services and bioinformatics. [269] Pfizer chose the company at the end of 2009 as apartner for integratedd rug discovery services after its acquisition of Wyeth, and terminated the acquired company's existing large-scale alliancew ith GVK Bio which had been in place since 2006. [23, 270] Sai Life Sciences was established in 1999, and steadily expanded its chemistryc apabilities in drug discovery, process R&D, and manufacturing, and more recently included biologya nd DMPK. [271] Since 2009, the company has been involvedi nad iscovery chemistry collaborationw ith UCB.
[272] A more limited number of CROs took the risk of adopting ad ual business model,byi nitiating proprietaryp rojects in addition to externaldiscoverys ervices (Table 2) .
Advinus Therapeutics,b acked financially by the Ta ta Group, was established in 2005 by the former heads of research and drug discovery,r espectively,a tR anbaxy,w ho had held previous scientific positions at Bristol-Myers Squibb. [273] The company wasl aunched with ad ual business model,h aving pharmaceuticala nd agrochemical development services in Bangalore, and ad rug discoveryr esearch center in Pune, focusing on metabolic, inflammatory,a nd neglected diseases.A dvinus runs both proprietaryd rug discoveryprojects with the aim to out-license preclinical drug candidates, and collaborative discovery and development projects.T he company entered into collaborations with major companies including MSD, Novartis, J&J, Celgenea nd Takeda. [274] Advinush as been working on ap ipeline of proprietaryd rug discoveryp rojects, with its most advancedc ompound, GKM-001, ag lucokinase activatorh aving successfully completed a1 4-dayP hase 2p roof-of-concept study, [275] [276] [277] and backup compound GKM-002 at the preclinical level. [278, 279] So far,the company has been unable to find apartner for af urther development of thesec ompounds. Ar ange of preclinical compounds, initially developedf or various indications such as COPD, IBD, Parkinson'sD isease, or inflammatory and autoimmuned isorders, [280] have been repositioned more recently for immuno-oncology,i ncluding adenosine A 2A and A 2B receptor antagonists; [281, 282] Janus kinase and BTK inhibitors (Supporting Information Ta ble2a, entries169-177). [278, 279, [283] [284] [285] [286] However,a fter the departure of Advinus' managing director in May 2016, [287] as hift of the company's emphasis more toward discovery services,followed by arestructuringo fits operations, the future of these compounds has become uncertain. [288] Anthem Biosciences,i ncorporated in 2006a nd headquartered in Bangalore, is ab iotech company offering drug discovery and development,a sw ell as process research and manufacturings ervices. [289] Although the company does not work on proprietaryd rug discovery projects,ito wns intellectual property rights to novel HDAC inhibitors forc ancert herapy from an earlier collaborationw ith Portsmouth Te chnologies, av irtual drug discovery company, [290] and has plans to partner candidate compounds PAT-1102 33,a nd PAT-1118 for preclinical development (Supporting Information Table 2a , entries [178] [179] . [291, 292] Aurigene DiscoveryT echnologies was established 2002 in Bangalore as as ubsidiary of Dr.R eddy's Laboratories, to provide services in medicinal chemistry, structural biology and structure-based drug design. [293] The company rapidly evolved away from pure functional services towardi ntegrated, collaborative, risk-sharing drug discovery alliances, and grew in size, including in 2009 with the absorption of ad evelopment group in Hyderabad after Dr.R eddy's termination of all in-house R&D projects.W ith over 500 scientists, Aurigene's current therapeutic focus lies in immuno-oncology, epigenetics, precision oncology and selected targetsf or inflammatory disorders. Aurigene has enteredi nto al arge number of collaborations, including with Novartis, Merck KGaA, Debiopharm, Endo Therapeutics, and Asana Biosciences, which all successfully delivered development candidates. [23] The company initiated proprietary inhouse drug discovery projects in 2010, [294] using both smallmolecule and peptidic or peptidomimetic approaches, and announcedi ts first licensing agreement with Debiopharm on Debio-1142, an inhibitor of an undisclosed oncology pathway (2011) (Supporting Information Table 6a, entries 180-191) . [295] Aurigeneh as developedarange of inhibitors which block the signaling pathway of PD-1, or Programmed cell death 1, an immunoreceptor which plays an important role in negativelyr egulatingi mmuner esponses. Sequences of the extracellular domain of PD-1 that are critical for ligand-receptor interaction, served as startingp oints for the investigation of 7-to 30-mer peptidesd erived from human and murineP D-1 sequences, leadingt ot he discoveryo ft he 29-mer AUNP-12/W016A, licensedt oP ierre Fabre MØdicaments (2014, but returned at the end of 2015). [296, 297] Aurigene has also identified shorter peptides and small-molecule peptidomimetics, licensed to Curis, including CA-170/AUPM-170, ad ual PD-L1/V-domain Ig suppressor of T-cell activation( VISTA) inhibitor,w hich entered Phase 1m id-2016, and CA-327/AUPM-327, ad ual PD-L1/T-cell immunoglobulin and mucin-domain-containing molecule-3 (TIM-3) inhibitor,c urrently at ap reclinical development stage. In addition, the agreement with Curis includes CA-4948/AU-4948), an orally activei nterleukin-1 receptor-associated kinase 4( IRAK-4) inhibitor for precision oncology. [298] [299] [300] Aurigene is also targetinge pigenetic regulation mechanisms, for example with pan-BET inhibitors (BRD4/ BRD2/BRD3), such as ODM-207,aquinolin-2(1H)-one derivativew hich it licensed to Orion, andf or which IND enabling studies are currently being pursued. [301] [302] [303] Additionally,t he companies are also exploring selectiveB ET inhibitors. Other projects continue internally with as trong focus on oncology,i ncluding with nicotinamide phosphoribosyltransferase (NAMPT) inhibitors such as AU-4869, [304] covalentK -Ras inhibitors, [305] or CDK7 inhibitors, [306] and RAR-related orphan receptor g (RORg)i nverse agonists for the treatment of inflammatoryd isorders. [307] Additional approaches targeted the treatment of infections with PD-1 inhibitors, [293] or with FabI (enoyl-acyl carrierp rotein (ACP) reductase)i nhibitors such as AEA16 34.
[308] GVK Biosciences,s et up in 2001, has becomeo ne of the largestc ontract research organizationsa nd has been engaged in major drug discovery service collaborations with companies such as Wyeth, Endo, or Medivir. [309] In 2013, GVK Bio formed aj oint venture with Onconova forl ead optimization and subsequent development for IND filing on two early research compounds, [309] including GBO-006-1 (previously ON-1231320), aP LK2 inhibitorf or the treatment of breast cancer, which appears to have been discontinued. Around2 014, GVK Bio initiated internal projects, with the aim to license these at an early stage to potential clients. As af irst example, GVK-TrkI, as elective tropomyosin receptor kinase A( TrkA) inhibitor for the treatment of cancer, progressed into preclinical development (Supporting Information Table 6a , entry 192) . [310, 311] As econd project with GVK01406, ac ompound targeting PI3Kb inhibition, reached the lead optimization stage. [312] 3.4. The rise of drug discovery at biotechnology companies
The launch of startupsa nd small biotechnology companies with the aim to generate IP and licensing revenues by discovering new drugs andb yp artnering these for development, is am ore recent addition to the country's pharmaceutical envi- ronment. This is due to the significantly higher risk involved, which some companies compensatei np art by generating arevenuestream from offering, in addition to discovery collaborations, ar ange of discoverya nd development services to Indian andg lobal companies.
Kareus Therapeutics was established in 2007b yf ormer members of Dr.R eddy's Laboratories, and runs currently as av irtual company headquartered in Switzerland. [313] The company's activities focus on CNS diseases,d iabetes and chronic pain. Kareus currently has two compounds in development in the US, namely KU-046,i nP hase 1s tudies for the treatment of Alzheimer's disease, [314] exploring furthero ptions for multiple sclerosis and fragile Xs yndrome, claimed to be acting by dual targetingo fo xidative stress and energy deficiency by linking niacin derivativesa nd redox-activea romatic compounds, and KU-5039f or diabetes, [315] likely to be af attya cid analogue activator of AMPK (Supporting Information Ta ble 6a, entries193 -194) .
Connexios Life Sciences was established in 2003, backed financially by the venture investinga rm of ac o-founder of Infosys, one of India's largest IT service companies. [316] The company focused initially on developing systems biology approaches, databases and cell-based assays, but in 2008, took the strategic decision to launch full-scale drug discoveryo perations, specializing in metabolic diseases such as type 2d iabetes. Connexios' most advanced compounds are CNX-012-570,a nA MPK activator for the treatment of type 2d iabetes, recently licensed to Boehringer Ingelheim, [317, 318] CNX-011-67, aG PR40 agonist, [319] for which the company has been looking for development partnerss ince 2012;C NX-013-B2, an activatoro fr etinoid Xr eceptor (RXR) a,b,g; [320] andC NX-010-49, a bHSD inhibitor (Supporting Information Ta ble 6a, entries [195] [196] [197] [198] . [321] Connexios counted around 200 scientists in discoveryb efore it restructured its activities to focus on its developmentp rogram, and no recent update has been given on the fate of the company's earlier stage compounds.
Rhizen Pharmaceuticals S.A. was incorporated in Switzerland, with the aim to develop and partner compounds originating from Incozen,abiotechc ompany founded in 2008 in Hyderabad to discovern ovel treatments for oncology and inflammation (Supporting Information Ta ble 6a, entries [199] [200] [201] [202] [203] [204] . [322, 323] Both companies were established with funding from Alembic Ltd. (see above). In 2012 RP-5264 (now TGR-1202) 35,aselective PI3Kd inhibitor for the treatment of hematological lymphomas, [324] was licensedt oT GT herapeutics, and has recently enteredP hase 3s tudies as ac ombination treatment together with TGR-1101, an anti-CD20 monoclonal antibody (mAb) for chronic lymphocytic leukemia. Phase 2s tudies with TGR-1202w ere still ongoing as as tand-alone treatment in 2016. [325, 326] Recently RP-6530, or tenalisib 36,adual PI3Kg/d inhibitorf or the treatment of hematological malignancies, entered Phase 1s tudies. [324, 327, 328] Furtherc ompounds reached different stages of preclinical evaluation, [329] including RP-1400, ac -Met kinase inhibitor, [330] abandoned in 2015, and RP-3128, aC RAC inhibitor. [331] RP-6503, an inhaled dual PI3Kg/d inhibitor, was licensed to Novartis at the end of 2015 for the treatment of airway diseases, and is potentially structurally related to arecently patenteds ingle enantiomer. [332] In 2016 Rhizen disclosed PR10107, ag lutaminase inhibitor for the treatment of cancer. [329] In addition, the company is developing RV1001, aP I3Kd inhibitor for veterinarian use in canine lymphoma (Phase 2). [329] Sphaera Pharma was launched in 2008, with laboratory space in Manesar,H aryana, andh eadquarters in Singapore. [333] The company filed af irst patent in 2011o nP I3K/mTOR inhibitors, [334] of which one, SPR965, has reached the preclinical evaluation stage. [335, 336] The compound is likely to be structurally related, if not identicalt oac ompound recently described in ap ublication. [337] In 2015, Sphaera announced ac ollaboration with the International Centre for Genetic Engineering and Biotechnology (ICGEB), funded by the WellcomeT rust for the development of inhibitors of niacin receptor1 (NIACR1), also knowna sG PR109A, to treat multidrug-resistanti nfections, that led to SPR113 which enteredpreclinical development (Supporting Information Table 6a , entries [205] [206] . [338] [339] [340] Curadev was founded 2010 in Noida, and currently employs around5 0p eople. [341] The company has integrated drug discovery activities, offerings ervices and in parallel workingo n proprietaryp rojects. In 2010, Curadev entered into ar esearch collaboration with Endo Pharmaceuticals for cancer up to candidate selection stage, and in 2011, ac ollaborationw ith Medivation. Curadev's most advanced internal program on dual indoleamine 2,3-dioxygenase (IDO)/tryptophan-2,3-dioxygenase (TDO) inhibitors, originating from its Endo partnership,i sa t the preclinical developments tage. Its lead compound CRD1152 (now RG70099) has been licensed to HoffmannLa Roche in April 2015 (Supporting Information Ta ble 6a, entry 207). [342] [343] [344] [345] Shantani Proteome Analytics,f ounded in 2010 in Pune, offers chemical proteomics servicesint arget identification,t oxicity profiling, or drug repurposing.
[346] More recently the company enteredt he field of drug discovery with ap roprietary project to treat type 2d iabetes, and af irst-in class lead compounda tt he preclinical stage. [347, 348] This is likely related to ar ecently published patent application by Shantani on indazole compounds including NDS100179 37,t ogether with the Council of Scientific and Industrial Research (CSIR) and the National Chemical Laboratory (Supporting Information Ta ble 6a, entry 208). [349, 350] Vyome Biosciences was founded in 2010, and currently consists of at eam of around 30 scientists. [351] The company focuses on dual-action compounds joining two known antibiotics by ac hemical linker, [352] and on conjugate-based antifungal and antibacterial products, by derivatizing existing drugs with ah ydrolytically or enzymatically labile linker and ac arrier, including fatty acids, surfactants or polymers to formulate the drug into nanoparticles. [353] VB-1953, ad ual-acting compound likely to combine anitro-imidazole antibiotic and afluoroquinolone joined with al inker moiety,i sV yome's first NCE to be approvedbythe FDA for Phase 1studies (SupportingInformation Ta ble 6a, entries [209] [210] . [354] As econd, unnamed compound recently entered preclinical studies. [355] Vitas Pharma is as mall startup drugd iscovery company founded in 2011, based in the Te chnology Business Incubator at the University of Hyderabad, with currently about 10 people. [356, 357] The company focusses on developing treatments for infectious diseases,p articularly,d rug-resistant nosocomial infections. The most advanced compound, presumably VT-02-00068 38 or an analogue thereof, [358] prevents fatty acid biosynthesis, av ital metabolic pathway in bacteria, by inhibiting the enzyme FabI, and is currently undergoing safety and toxicity testing( Supporting Information Ta ble 6a, entry 211). [359] It is equallypotent againstd iverse MRSA strains.
Invictus Oncology,i ncorporatedi n2 011a nd based in New Delhi, developsn anotherapeutics for cancert reatment. [360] Invictus has licensed the rights to at echnology developed at HarvardM edical School, consisting in decreasing the toxicity of platinum-based anticancer drugs by conjugating them to cholesterol, and assemblingt hem into nanoparticles. [361] As tested on cisplatin, the increased nanoparticle size allows the drug to enter cancerc ells, whichh ave wide pores on their surface, but not normal cells, with reduced pore sizes. The company is also applying the technology to its own new platinum drugs as well as antibodyd rug conjugates. IO-125 39,t he company's lead compound, is undergoing preclinical development studies (Supporting Information Ta ble 6a, entry 212). [362, 363] Krish Biotech was established in 2009 near Kolkata to offer preclinical services including analytical and toxicological testing.
[364] In 2015, the company initiated drug discovery efforts, led by former Piramal scientists, in the areas of metabolic disorders, oncology,i mmunology,p ain and inflammation. With the aim of building ap roprietary research pipeline, including through the acquisition of external compounds, Krish Biotech in-licensed two preclinical stage compounds from Piramal: KBR1001 (or KBRPL1001), aR ORgta ntagonist for the treatment of autoimmunea nd inflammatoryd isorders, [365] and KBR2001 or (KBRPL2001), aG PR120 agonist for diabetes and metabolic disorders. [366] Three additional projects targetingo ncology and pain are currently at the discovery stage (Supporting Information Ta ble 6a, entries 213-214).
[367]
Results and Discussion
Proprietary drug discovery at Indian companies
Our analysisi dentified 28 major Indian pharmaceutical companies and 14 biotech and startup companies that have reported proprietaryN CE R&D with preclinical or clinical development compounds between 1994and mid-2016( Ta bles 1a nd 2).
Among top-100 pharma companies, overall R&D size and productivity vary considerably,h owever,a nd only 12 companies have engaged in long-term and large scale drug discovery efforts, and have produced as ignificant number of development compounds (Supporting Information, Ta bles 6-8). For the majority,drug discovery remained arather limited activity,asi llustrated for example, by isolatedp atenting of internal research results, or by academic collaborations.
Few CROs have ventured successfully into proprietary research. Advinus had been ap ioneer in this field since its inception in 2005, although the failure to license out as ingle of its internal compounds has recently led to ar efocus of the company's activities, and it remains to be seen if the current discovery pipeline survives. Aurigenei sc urrently leadingt he way, with as trong proprietary portfolio and four out-licensed compounds, and two more under an option agreement. The number of biotech companies and startups with proprietary development compounds remains smallwith 10 companies.
Since the initiation of drug discovery by Dr.R eddy's Laboratories in 1994, Indian companiesh ave disclosed at otal of 214 proprietaryp reclinical and clinical stage development compounds, of which 168 originatedf rom large pharma companies, and 46 from contract research and biotech companies. Of these, 83 compoundsw ere progressing in the pipeline by mid-2016 according to publicly available information (Figures 2a nd  3, Supporting Information Tables 8a and8 b) . Given the inherent fluctuationso fR &D pipelines, this number is likely to evolve as more information becomes available on existing pipelines (e.g.,A dvinus, Connexios), and as additional development compounds will be disclosed.
Despite this significant number of compounds, Zydus Cadila's saroglitazar,l aunched in 2013, remains so far the only compound that was entirely discovered and developed by an Indian company.T hreem ore compounds reached the level of Phase 3s tudies:D r. Reddy's ragaglitazar and balaglitazone, both discontinued, and more recently,R hizen's RP5264/TGR-1202, in combination with an anti-CD20 mAb,l icensed to TG Therapeutics. Phase 2s tage compounds peakedi n2 012 with 15 compounds, but this figure has decreased slightly since. At the major pharmaceutical companies, many internal R&D efforts have not been met with the expected success, as seen from those companies that have abandoned drug discovery in the meantime, be it after being acquired (Dabur,M atrix, Ranbaxy), before going public (Alkem), or after failing to deliver commercial compounds despite significant investments (Dr. Reddy's, Piramal).O ther companies have significantly reduced the number of NCEs in their pipeline, including Zydus Cadila (from 13 in 2011t o5in 2016), Glenmark (from 8i n2 006 to 2 in 2016), and Sun (from 5i n2 012 to 3i n2 016). One significant exception to this is Lupin Pharma, which restructured completely its R&D organization in 2010 andl aunched ar ange of new NCE projects,w ith currently 4c ompounds undergoing clinicald evelopment. As an overall result, however,t he combined pipeline contribution by major companies has fallen from ap eak in 2011w ith 58 compounds (89 %o ft otal pipeline), to 41 compounds (or 49 %o ft otal pipeline) in 2016.
Biotechnology and startup companies, in contrast, have grown in number,s ize and research output,a si llustrated by an increasing number of early development stage compounds, led currently by Aurigene. Several of the more recently founded companies have also been successful in generating preclinical compounds that attracted globalp artners, such as Rhizen Reviews Pharmaceuticals,C onnexios, and Curadev.T he increase in development compounds coming out of India is thus currently entirely driven by R&D focused biotechc ompanies, which for the first time surpassed pharma companies with 42 compounds in 2016, growing from 2% of the overall pipelinei n 2009 to 51 %in2 016. Whereass ome of the major Indian pharmaceutical companies have the ambitiont od evelop and market their own drugs, high costs and long timelines,c ombined with the lack of experience in clinical development lead most, and in particular smaller biotech companies, to prefer out-licensing deals to financep art or all of their development costs. [22] This is illustrated by the fact that 23 small-molecule compounds have been licensed to global pharmaceutical companies or have been under option agreements over the past two decades (Table 3) .
Initially dominated by major pharmacompanies, in particular DRL, Ranbaxya nd Glenmark, the out-licensing model experienced severalr esoundingf ailures, including in Phase 2s tudies, which led some analysts to claim the death of the Indian outlicensingm odel. [14] Whereas the steady decrease of licensed compounds appearst oc onfirmt his for large Indian pharma companies, the reversei st rue for biotech companiesw ith 10 licensing or option agreements since 2011, largely led by Aurigene, and illustrates the continuing attractiveness of Indiandevelopment compoundsf or global companies.
Development compounds by indication and target class
Counting all, including multiple indications targeted by these development compounds, endocrinology and metabolic disorders, together with oncology dominate the therapeutic areas, representing almosth alf of all indications covered by drug discovery projects in India, followed by infections,i mmunological and rheumatological diseases, neurology and pulmonary and respiratory diseases.A ll remaining disease areas combined represent less than 10 % ( Figure 4 , SupportingI nformation Ta ble 8c). Thisd istribution is clearly quite different from the burden of diseases in India itself, where the leadingc ausesa re maternal and neonatal conditions, followed by cardiovascular diseases and diabetes, various infectious diseases, neuropsychiatric conditions, respiratory diseases and cancer,a nd corresponds more to the needs resultingf rom the leading Western diseases,t hat is, diabetesa nd cardiovascular disorders, cancer and neuropsychiatric conditions. [368] With the exception of startups, few Indian companies have specialized entirely in particulard isease areas, such as Wockhardt in anti-infectives, Suven in CNS diseases, Natco andJ ubilant in oncology,o ra tl east partially,s uch as Zydus Cadila in metabolic disorders, or Aurigene with as trong focus on oncology.T he majority of Indian companiesh ave opted to spread their efforts over multiple therapeutic areas ( Figure 5 , Supporting Information Table 8d ).
If one groups all development compounds by target class, including multiple modes of action, the top-3 of the resulting 23 classes,t hat is, GPCRs, kinases, and nuclear signaling pathways, represent about half of all targets (46 %) ( Figure 6 , Supporting Information Ta ble 8e). Few companies have focusedo n specifict argets,s uch as Suven on 5-HT 6 receptors, or Wockhardt on fluoroquinoline and oxazolidine type antibiotics, and some others have ab ias towardc ertain target classes, such as Aurigenea nd its kinase platform, buti ng eneral companies adopted ab road approachwith multiple target types.
Novelty of projects
Of all new FDA-approved NCEs between1 999 and 2013, almosto ne third are first-in-class compounds, as modulators of an until then unprecedented target or biological pathway, [369] and the shareo fp otentially first-in-class drugs in the current globalp ipeline has been estimated to be on average 70 %. [370] India'sp ast and current discovery pipeline is far from reaching However,t his does not mean that Indian companies are not innovating in drug discovery. Even though Zydus Cadila's saroglitazarh as only been one of many glitazars that entered development,i th as been the first one to reach the market in 2013. Fifteen years earlier,D r. Reddy's had been among the first companies to work on glitazars, with ragaglitazar reaching Phase 3t rials before being abandoned. Glenmark's GRC-15300 had been the first TRPV3 inhibitor to enter clinicalt rials, and the company's GRC-17536 hast he potential to become af irstin class TRPA1 inhibitor for the treatment of pain. [161] Advinus' glucokinase activator,a lthough only one out of more than 20 compounds that have entered clinicalt rials, is an orallya vailable, potential first-in-class drug with the advantage over earlier,d iscontinued development compounds of being liver-selective with al ower hypoglycemiar isk. [371] Sun's Bcr-Abl tyrosine kinase inhibitors SUN-K706 and follow-on compound SUN-K954 are active against native Bcr-Abl as well as Abl T315Im utations, the most resistantf orm of mutation in leukemic cells, and are more selective with respecttoar ange of other kinases inhibited by ponatinib, the currently used benchmark inhibitor, which might contributet ot hat compound's toxicity profile which limits its clinicalu se. [126] Whereas several of Aurigene's programsa im at developing best-in-class compounds with significant improvements over competitors (for example, its inhibitors of BET,N AMPT,o rF abI), the company's PD-1 inhibitors licensed to Curis are the first highly potent and orally available small-molecule compounds targeting Programmed cell death-1. CA-170, which has recently been nominated as development candidate, is af irst-in-class dual-acting molecule targeting both Programmed cell death ligand-1 (PD-L1) and V-domain immunoglobulin suppressor of T-cell activation (VISTA). [299, 300] Jubilant's JIEM-0186i ss pecifically targeting non-smallc ell lung cancer associated with EGFR mutants L858R or T790M,a nd showsahigh selectivity against cells carrying the wild-type EGFR. [237] Amongt he smaller companies, Curadev is targeting ah ighly competitive area with its potentially first-in-class dual IDO and TDO inhibitors, [372] and Shantani, based on the use of its proteomics platform, has reported an early development compound with an ovel mechanism of action fort he treatment of type 2d iabetes. [348] Successr ates and time spent by development phase have been widely used as parameters to quantify efficiency in pharmaceutical R&D. [373] [374] [375] Currents uccess rates by phase are defined as the number of development compounds that advance to the next phase, divided by the number of compounds that enteredt he phase from which is subtracted the number of compounds of yet unknown fate, for example, those in ongoing studies.
We have compiled availabled ata (Supporting Information Ta ble 7) on attrition and timelines for the 214 compounds that enteredp reclinical development, of which 82 progressed to Phase 1, 34 to Phase 2, and 4t oP hase 3, with 1c ompound launched. Although the very low number of drug candidates reachingP hase 3, togetherw ith the lack of precision in collection timelines do not allow us to generate statistically significant values for all variables, we still believe our analysist ob e of relevance, as it illustrates for the first time ever efficiency trends in Indian drug discovery,w hich allow ac omparison with industry figures ( Table 4, Supporting Information Table 8f ).
With the exception of Phase 1t rials, for which the success rate of 54 %l ies wellw ithin the range reported fori ndustry, the chances for successfully transitioning to higher phases are considerably lower at Indian companies than the industry average. The very low successr ate of 17.4 %d uring Phase 2t rials could hint at an overall less efficient selectionp rocess during earlier phases, and therefore expensive terminationsi na dvancedstages. This is particularly true for the three major companies that abandoned drug discovery( Dr.R eddy's, Ranbaxy and Piramal), with 9o ut of 11 compounds failing in Phase 2, and none completing successfully Phase 3s tudies, where 2o ut of 2f ailed. These lower success rates are compounded by the increased times pent by phase, especially at the earlier stages. Even if the nearly twofold increase in time spent at the preclinical level could be in part the result of capturing witht oo little precision this first stage of development, clinicalp hases, too, take considerably longer to complete, and make the drug discovery process at Indian companies considerably less efficient than the industry average. It remains to be seen if the large number of compounds that have enteredd evelopment between 2007 and 2016, and of whichm anya re currently progressinga tt he early stages,w ill be able to modify this trend significantly.I tw ould also be interesting to comparet he Indian success rates to those of other emerging countries, but these are to our knowledgen ot yet availablei nt he public domain.
Drug discovery and R&D investments
All major Indian pharmaceutical companies with significant drug discovery and development activities have reported considerable R&D expenditures in their annual reports, usually in the range of 5-10 %o fr evenues.H owever,i tm ust be pointed out that NCE research is in general only am inor component of this, and that the biggerp art goes towardg enerics development, formulation and drug delivery technologies, or process R&D. This can be assessed from those cases where drug discovery expenditure is specificallym entioned, or can be calculated from available data. Based on these, we estimate that an average of 20-30 %o ft he total R&D budget is dedicated to NCE research and development, even though somea nalysts estimate that in specific cases as little as 10 %g oes to new discovery research. [5] Assuming even an average spending on NCE R&D of 25 %o ft otal R&D expenditures,t his brings the overall investment in new drug discovery and development down to around2%, abouto ne tenth of the average spend on R&D by the US pharmaceutical industry,w ith about20% of sales. [376] 
Conclusions and Outlook
Since the initiation of drugd iscovery by major companies in the 1990s, Indian pharmaceutical R&D efforts have resulted in over 200 preclinical-and clinical-stage development compounds, of which only one has reached the market thus far. This illustrates the tremendousa ccumulation of R&D capacity and of know-how that has occurred over at imes pano ft wo decades, and at the same time its weakness in terms of efficiency. With slightly over 80 active pipeline compounds,I ndia is far from being the drug discoveryp owerhousei to nce had the ambition to become. The fact that several of the large investors in pharmaceutical R&D have closed down their drug discoveryu nits in the meantime, and that others have decreased their pipeline, shows to what extent the industry, which had been familiarw ith the generics business, had underestimated the challenges that come with innovative NCE discoverya nd development. This is likely due to ar ange of factors. One is as kill gap. The Indian Patent Act of 1970, with its focus on process patents and generics manufacturing, despite the social good it did in India, anda rguably worldwide, by making good qualityg enerics affordable to poor countries, removeda ll incentives to discover new medicines. [20] The consequence was ar apid loss of skills, as Western companiesc losed their research departments, and as drug discovery-related disciplines, including medicinal chemistry,b iology andp harmacology,d eclined in the Indian science educations ystem. [20] These skills were again built up gradually by the pioneerp harma companies, and accelerated with the rise of contract research companies, as these evolved from custom synthesis, into highera dded value services including medicinal chemistry,d iscovery biology,i nvivop harmacology,D MPK, and early toxicology models. [20] This has been possible at the expense of in-house training, since ar ecent industry survey estimated that 66 %o ft he existing manpower is not industry ready,h ighlighting the misfit between academic training and industry needs. [377] Some of the basic problems that need to be addressed in order to strengthen weaknesses in the scientific education system have been summarized in recent reports. [377] [378] [379] [380] Ac ertain number are due to internal issues, such as inadequate facilities andq uality of teaching, bureaucracy and political influence. Others are ac onsequence of the historical deficiencyo f interactions between industry and academia or public research institutions, because existing collaborations are still considered by al arge majority as "limited", and by only 10 %a s" good", due to the lack of interest for "applied science", profoundd istrust, or different priorities and key performance indicators, such as publications in academia versus patents and commercializationini ndustry. [19, 377, 381] All prevents cience from being considered as an attractive career path, with as ac onsequence as evere brain drain, as 40 %o fI ndia-born researchers were working overseas in 2011. [382] As eries of initiatives have been launched,a iming to attract experienced returnees, that is, researchers who have spent part of their scientific careera broad, back into the country with ar ange of fellowships in all areas of science and biotechnology.W ith an estimated figure of 750 fellowshipss ince 2006, these are, however,l ikely to be insufficient for the country's needs. [383] [384] [385] [386] The industry itself has also evolved, but needs to progress further. Thereh as been ag radual shift in contributionst ot he growingp ipeline away from the established pharmaceutical companies, whose contribution peakedi n2 011, towards maller,r esearch-intensive biotechnology companies. These do not only benefitf rom the availability of trained scientists with relevant industrial experience in the country,b ut also tend to focus on specific disease areas or target classes, which gives them the opportunity to carve out niches to be successful in their particulara reas of expertise, as illustrated by an umber of recent licensing deals. The industry has startedt oi ntegrate the importance of innovation, and is movinga way from low-risk follow-on projects, which certainly decreased the risk, but on the other hand led to molecules withoutpreclinical and clinical advantages over existingd evelopment compounds, and were therefore difficult to out-license. Current projects are targeting increasingly best-in-class compounds that address specific issues of compounds currently progressing in the globalp ipeline, if not compoundst hat have the potential to become firstin-class drugs.
There are, however, other weaknesses that need to be addressed. Overall investment in R&D, and more specifically in NCE drug discovery,n eeds to be increased, as it hasb een lagging far behind globali ndustry average. More biotechnology companies need to be created, and funded appropriately.T he US is home to over 40 pharmaceutical companies and an estimated 1700 biotech companies, which dwarfs India's life sciences landscape. [387] India is, however,m aking progress in putting in place an ecosystem whichi sm ore conducive to biotechnologye ntrepreneurship, through as eries of grant schemes to foster innovation, and bio-incubators which provide space, accesst os cientific equipment, connections to industry and mentorship for IP management to startup companies. [388] The implementation of biotech parks and clusters, in particular, to promote research andi nnovation, by establishing stronger links between institutions active in life sciences R&D, biotech and pharmac ompanies, innovative small and medium size enterprises, haso ver the past years proven extremely valuable to attract companies, for example, in the area around Bangalore with around 200 companies, or Genome Valley in the vicinity of Hyderabad, with over 150 enterprises. Several more are in the planning phase. [389, 390] The Indian Government aims to stimulate the launch of 2000 startupsi nl ife sciences over the coming five years. [391] It is, however,u ncertain how many of these will venture into proprietaryN CE projects,a ss of ar drug discovery has been considered the least attractive from an investment standpoint, ranking last of 12 options, far behind diagnostics, medicaldevices, or discovery services. [377] This low attractivenessi sc ompounded by structuralw eaknesses across the entire sector, such as insufficient understanding of IP protection,r egulatory uncertainty regarding clinical trials, unethical practices, or pricing uncertainties. [380, 392] All these contribute to raising barriers, and therefore need to be fixed.
It remains to be seen if and how fast industry initiatives and government efforts will be able to bring about the required changes.I nt he meantime, the country has already scaled back its highly ambitious, if not unrealistic, goal, whichi n2 010 had been part of the government's "Pharma Vision 2020", to have "one out of five to ten new drugs discovered in the world originating from India by 2020", [393] which would have represented an average of at least three to six new medicale ntities (NMEs) per year,t oamore realistic, but still highly ambitious target of "one NME per year and 10-12 incremental innovation launches per year by 2030". [394] The comingy ears will be critical. "Success will breed success", as tatement made by one of the industry leaders at ar ecent biotechnology convention in Hyderabad,m ight be true, but it still requires success stories to initiate, then to fuel the process.
